Difference between revisions of "MEDICATION-LIGNOCAINE"
From NeuroRehab.wiki
(Imported from text file) |
(Imported from text file) |
||
| Line 4: | Line 4: | ||
==Reference(s)== | ==Reference(s)== | ||
Gale, M., Grantham, H., Morley, P. and Parr, M. (2016). Advanced Life Support Level 1: 3rd Australian Edition. Australian Resuscitation Council. | Gale, M., Grantham, H., Morley, P. and Parr, M. (2016). Advanced Life Support Level 1: 3rd Australian Edition. Australian Resuscitation Council. | ||
American College Of Surgeons. Committee On Trauma (2012). ATLS : student course manual. Chicago, Ill.: American College Of Surgeons. | <br/>American College Of Surgeons. Committee On Trauma (2012). ATLS : student course manual. Chicago, Ill.: American College Of Surgeons. | ||
[[Category:Medication]] | [[Category:Medication]] | ||
[[Category:Advanced Life Support]] | [[Category:Advanced Life Support]] | ||
Revision as of 01:50, 17 December 2022
1. Acts as a membrane stabilising agent, used for its anti-arrhythmic effects.
2. Indications: VF/pulseless or VT refractory to defibrillation.
SE
3. Nausea & vomiting.
4. CNS: slurred speech, drowsiness, seizures.
5. CVS: bradycardia, heart block, asystole.
DOSAGE
6. Initially 1 mg/kg bolus after the third DC shock, additional bolus of 0.5 mg/kg (up to 200 mg) may be considered.
Reference(s)
Gale, M., Grantham, H., Morley, P. and Parr, M. (2016). Advanced Life Support Level 1: 3rd Australian Edition. Australian Resuscitation Council.
American College Of Surgeons. Committee On Trauma (2012). ATLS : student course manual. Chicago, Ill.: American College Of Surgeons.
